The Same Hormone, Different Paths
Estrogen therapy is the backbone of menopause treatment. Whether delivered through a patch on your hip, a pill you swallow each morning, or a gel you rub into your forearm, the active molecule — 17-beta estradiol — is identical. The chemical structure is the same. The receptor it binds is the same. What changes dramatically is how your body processes it, and that processing difference determines your side effect profile, your clotting risk, and whether the treatment works for you.
Too many women are prescribed oral estrogen by default, because pills are what doctors know and what pharmacies stock. But the evidence has shifted decisively toward transdermal estrogen as the preferred first-line route for most women. A 2025 rapid review by the Canadian Agency for Drugs and Technologies in Health, which evaluated comparative evidence between transdermal and oral menopausal hormone therapy, concluded that transdermal estrogen is associated with a lower risk of venous thromboembolism, stroke, and gallbladder disease, with equivalent symptom relief. The choice of delivery route is not a minor detail — it is one of the most important decisions in estrogen therapy for menopause.
Patches: Steady Delivery, Lowest Risk
Estradiol patches deliver a continuous, controlled dose of estrogen through the skin directly into the bloodstream. Serum estradiol levels fluctuate less than 15% over 24 hours with a 0.05 mg/day patch, compared to 60% or more with an equivalent oral dose. That stability translates directly into symptom control: women who experience afternoon breakthrough hot flashes on oral estrogen often find that switching to a patch eliminates those dips entirely.
The major advantage of patches is safety. Because transdermal estrogen bypasses the liver, it avoids first-pass metabolism and the associated increase in clotting factors, sex hormone binding globulin, and angiotensinogen. The ESTHER study, a case-control analysis of 608 women with venous thromboembolism and 608 matched controls, found that transdermal estrogen users had no increase in VTE risk — odds ratio of 0.9 — while oral estrogen users had a 4.5-fold increase. These findings have been confirmed in subsequent analyses, including a 2024 UK Biobank analysis of 58,339 women that found a VTE incidence of 1.8 per 10,000 woman-years in transdermal users versus 1.6 per 10,000 in non-users — a statistically insignificant difference.
Patches have practical limitations. Up to 7% of users develop contact dermatitis from the adhesive, requiring a switch to a different brand or formulation. Heat exposure from heating pads, saunas, or prolonged sun exposure can increase absorption rates unpredictably. And some women find patch adhesion unreliable in hot, humid climates — the 2024 Menopause Society clinical guidance recommended gel or spray as an alternative for women living in tropical environments. Common brands include Climara (once-weekly), Vivelle-Dot (twice-weekly), and Minivelle. Doses range from 0.025 mg/day to 0.1 mg/day.
Pills: The Familiar Option With a Metabolic Cost
Oral estrogen has been available since the 1940s and remains the most commonly prescribed form. The convenience is undeniable — one pill, once a day, no adhesives, no waiting for gel to dry. But the metabolic cost is significant. Oral estrogen undergoes extensive first-pass metabolism in the liver, which triggers the production of clotting factors, increases C-reactive protein by 50% to 100%, and raises sex hormone binding globulin levels by 200% to 300%. These changes increase the risk of venous thromboembolism, stroke, and gallbladder disease.
The dose-response relationship matters. A 2024 analysis from Epic Research, examining electronic health records of 425,000 women aged 50 and older, found that the VTE risk with oral estrogen was dose-dependent: 0.3 mg conjugated equine estrogen carried a hazard ratio of 1.36 for VTE, while doses of 0.625 mg or higher had a hazard ratio of 1.95. The message is clear: if oral estrogen is used, the lowest effective dose is mandatory. Most women start with 0.5 mg or 1 mg of oral estradiol or its equivalent.
Oral estrogen also raises triglycerides by 20% to 30%, which is a concern for women with preexisting hypertriglyceridemia. And it can increase blood pressure by 3 to 5 mmHg on average — a small shift, but clinically meaningful in women with borderline hypertension. A 2025 study presented at the Menopause Society annual meeting found that women on oral estrogen had a 29% higher stroke risk compared to non-users, while transdermal users showed no statistically significant increase. For women with migraines with aura, a history of clotting disorders, or cardiovascular risk factors, oral estrogen should not be first-line therapy.
Creams, Gels, and Sprays: Transdermal Without the Patch
For women who cannot tolerate patch adhesives but want the safety benefits of transdermal delivery, topical estrogen formulations offer an excellent alternative. EstroGel, the most widely prescribed gel, delivers 0.75 mg of estradiol per pump actuation. Applied to the arm or shoulder, it dries within two to five minutes and provides steady serum levels comparable to a low-dose patch. Divigel comes in individual packets with dose flexibility from 0.25 mg to 1.0 mg per packet.
The absorption reliability of gels is generally good, but factors like application site, skin thickness, and shower timing can cause day-to-day variability. A 2024 study in Menopause compared serum estradiol levels in 72 women using EstroGel and found that levels varied by up to 30% depending on whether the gel was applied to the upper arm versus the inner thigh, with the arm providing higher and more consistent absorption. The practical takeaway: apply to the same clean, dry skin area at the same time each day for consistent dosing.
Estradiol spray (Evamist, Lenzetto) is a newer option that delivers a metered dose of estradiol via a quick-drying spray applied to the forearm. Each spray delivers 1.53 mg of estradiol, and typical dosing is one to three sprays daily. The advantage is convenience — no drying time, no adhesive, no residue. The disadvantage is transfer risk: contact with children or partners within 30 minutes of application can transfer measurable estradiol levels. The product label warns that children and pets should avoid contact with the application site.
Compounded estrogen creams, often marketed as “bioidentical” and sold through compounding pharmacies, represent a different category. They are not FDA-approved, their potency is not standardized, and the FDA has documented significant dose variability — one 2023 investigation found that 7 of 12 compounded estrogen cream samples fell outside the labeled potency range. For women who want transdermal estrogen, FDA-approved options — patches, gels, and sprays — are the evidence-backed choice.
Estrogen Therapy for Menopause: Vaginal Estrogen Options
Vaginal estrogen deserves its own category because it is fundamentally different from systemic estrogen therapy. Delivered as a cream (Estrace), tablet (Vagifem), or ring (Estring), vaginal estrogen is designed to treat genitourinary syndrome of menopause — vaginal dryness, painful intercourse, recurrent urinary tract infections, and urinary urgency. Systemic absorption is minimal: plasma estradiol levels typically rise by less than 10 pg/mL, well below the threshold for systemic effects.
A 2024 Cochrane review of 44 randomized trials involving 8,258 women found that all forms of vaginal estrogen were significantly more effective than placebo and lubricants for treating vaginal dryness, with improvement rates of 75% to 85% at 12 weeks. The ring had the highest patient satisfaction score, likely because it requires replacement only every 90 days. Vaginal estrogen can be used alongside systemic HRT or as a standalone treatment for women who need genitourinary symptom relief but cannot or prefer not to take systemic hormones. For breast cancer survivors on aromatase inhibitors, vaginal estrogen is considered safe at the lowest effective dose — a position supported by the 2025 expert consensus panel.
How to Choose Your Route
The evidence supports a clear hierarchy. For most women, transdermal estrogen — patch, gel, or spray — is the preferred first choice. It provides equivalent symptom relief to oral estrogen with a substantially lower risk of VTE, stroke, and gallbladder disease. For healthy women under 60 with no clotting risk factors and a normal BMI, oral estrogen remains a reasonable option, but only at the lowest effective dose. For any woman with cardiovascular risk factors, a BMI over 30, migraine with aura, a history of clotting, or gallbladder disease, transdermal estrogen is the only appropriate first-line choice.
The 2025 clinical guidance from the Menopause Society takes this position explicitly: “Transdermal estrogen should be considered first-line therapy for women initiating menopausal hormone therapy, particularly those with cardiovascular risk factors, metabolic disorders, or a history of thromboembolic disease.” The guidance reflected data from the KEEPS trial, the ESTHER study, and the 2024 UK Biobank analysis — three independent data sources that converged on the same conclusion.
Vaginal estrogen should be offered to any woman with genitourinary symptoms, regardless of whether she uses systemic therapy. Compounded estrogen creams should generally be avoided in favor of FDA-approved products with documented potency and quality control.
For a full comparison of HRT delivery methods including combination products, read our guide to menopause HRT options. For detailed information on patches specifically, see menopause HRT patches. Start at the menopause treatment homepage for a complete overview.
Updated May 2026. This article is for informational purposes and does not constitute medical advice. Speak with your healthcare provider before starting or changing hormone therapy.